SEC Filing Summary: MedaSorb Technologies Corporation (Form 8-K)
Business Context and Reporting Period
Company: MedaSorb Technologies Corporation (Note: Request metadata listed "Cytosorbents Corp," but the filing identifies the registrant as MedaSorb Technologies Corporation).
Date of Report: June 25, 2008
Reporting Period: Current Report (Event-based)
The filing reports the completion of a private placement of Series B Preferred Stock and related amendments to existing security holder rights. The company is a Nevada corporation with its principal executive office in Monmouth Junction, New Jersey.
Key Financial Metrics and Capital Structure
Capital Raised: $4.275 million in gross proceeds from the sale of 42,750 shares of Series B 10% Cumulative Convertible Preferred Stock at $100 per share.
Debt Conversion: $175,000 in principal indebtedness was converted into 1,750 additional shares of Series B Preferred Stock.
Security Terms:
- Dividend Rate: 10% per annum, payable quarterly (increases to 20% upon default).
- Dividend Payment: Paid in additional shares of Series B Preferred Stock (cash payment option available under specific conditions).
- Conversion Price: Initial conversion rate is one share of Common Stock for each $0.035 of stated value.
- Liquidation Preference: Series B ranks senior to Series A Preferred Stock and Common Stock ($100 per share plus accrued dividends).
Capitalization Post-Closing:
- Common Stock Outstanding: 25,044,932 shares.
- Series A Preferred Stock: Convertible into 11,256,416 shares of Common Stock.
- Series B Preferred Stock: Convertible into 127,142,857 shares of Common Stock.
- Other Convertible Securities: Options and warrants exercisable for approximately 28,425,784 shares.
- Authorized Common Stock: 100,000,000 shares (insufficient for full conversion; reverse split or increase required).
Liquidity and Cash Flow: The filing does not provide specific cash flow statements, balance sheet totals, or current liquidity metrics beyond the proceeds from this transaction.
Material Changes Versus Prior Period
Series A Preferred Stock Amendments: Holders of Series A Preferred Stock consented to the issuance of senior Series B stock. Key changes include:
- Permanent waiver of anti-dilution protection for certain holders.
- Waiver of pre-emptive rights and rights of first refusal regarding the Series B placement.
- Waiver of all registration rights.
- Conversion Price Reduction: For participating Series A holders, the conversion price was reduced from $1.25 to $0.26.
Class A Warrants Amendments: Holders consented to a permanent waiver of anti-dilution protection. The exercise price for participating holders was reduced from $2.00 to $0.52.
Corporate Governance: NJTC Venture Fund SBIC, L.P. (lead investor) is entitled to elect two directors to the six-member Board and two members of the three-member compensation committee.
Guidance, Outlook, Risks, and Unusual Items
Future Funding Conditions: The conversion price of Series B and Class A Warrants is subject to further reduction if the company raises an additional $1.5 million from Series A holders or affiliates within 60 days of the closing (the "Additional Offering").
Registration Obligations: The company agreed to file a registration statement for the Common Stock issuable upon conversion within 180 days and have it become effective within 240 days.
Capital Structure Risk: The company currently lacks sufficient authorized Common Stock to accommodate the conversion of all outstanding securities. A reverse stock split or increase in authorized shares must be effected within 180 days.
Management Changes: New employment agreements were executed for the CEO, CFO, and COO. These agreements terminate on December 31, 2008, without automatic renewal. Stock options are no longer accelerated upon termination, and severance is limited to two weeks of base salary per year of service.
Investor Verification Checklist
- Verify the company's ability to raise the additional $1.5 million within 60 days to avoid further conversion price reductions.
- Confirm the timeline and shareholder approval for the required reverse stock split or increase in authorized shares to prevent conversion blockage.
- Review the specific terms of the "Additional Offering" and the impact of the conversion price adjustments on existing equity holders.
- Assess the financial impact of the 10% cumulative dividend paid in stock (compounding dilution) versus the potential for cash payments.
- Monitor the appointment of NJTC directors and their influence on the Board and compensation committee.